Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

ACADIA Pharmaceuticals Inc

Current price
14.87 USD +0.03 USD (+0.20%)
Last closed 14.84 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 456 836 096 USD
Yield for 12 month -37.63 %
21.11.2021 - 28.11.2021

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. Address: 12830 El Camino Real, San Diego, CA, United States, 92130

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

27.28 USD

P/E ratio

Dividend Yield

Current Year

+726 437 000 USD

Last Year

+517 235 000 USD

Current Quarter

+205 831 000 USD

Last Quarter

+231 041 000 USD

Current Year

+680 706 000 USD

Last Year

+507 069 000 USD

Current Quarter

+182 880 000 USD

Last Quarter

+213 150 000 USD

Key Figures ACAD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 6 069 000 USD
Operating Margin TTM 7.39 %
PE Ratio
Return On Assets TTM -0.38 %
PEG Ratio -0.42
Return On Equity TTM -0.41 %
Wall Street Target Price 27.28 USD
Revenue TTM 813 806 016 USD
Book Value 2.81 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 73.8 %
Dividend Yield
Gross Profit TTM 145 494 000 USD
Earnings per share
Diluted Eps TTM
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -0.21 %

Dividend Analytics ACAD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ACAD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ACAD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 26.3852
Enterprise Value Revenue 3.3623
Price Sales TTM 3.8877
Enterprise Value EBITDA -36.0111
Price Book MRQ 6.5412

Financials ACAD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ACAD

For 52 weeks

14.55 USD 33.99 USD
50 Day MA 15.97 USD
Shares Short Prior Month 11 978 676
200 Day MA 22.11 USD
Short Ratio 6.59
Shares Short 12 135 862
Short Percent 9.81 %

Dynamics of changes in the value of assets




446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds



203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics



2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics